# OnCo record nct04854668 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04854668/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04854668", "NCT04854668" ;
  schema:name "A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Can"@en ;
  schema:description "A phase 3 trial of Anlotinib, Bevacizumab, CAPOX in colorectal cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04854668/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04854668> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2021-05-27" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/anlotinib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/capox/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:companies <https://onco.cc/companies/sino-biopharm/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/> .